204 related articles for article (PubMed ID: 35912837)
21. New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.
Santoro A; Angelico G; Travaglino A; Inzani F; Arciuolo D; Valente M; D'Alessandris N; Scaglione G; Fiorentino V; Raffone A; Zannoni GF
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073635
[TBL] [Abstract][Full Text] [Related]
22. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
23. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Concin N; Creutzberg CL; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann JA; Bosse T; Chargari C; Fagotti A; Fotopoulou C; González-Martín A; Lax SF; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell DE; Querleu D; Raspollini MR; Sehouli J; Sturdza AE; Taylor A; Westermann AM; Wimberger P; Colombo N; Planchamp F; Matias-Guiu X
Virchows Arch; 2021 Feb; 478(2):153-190. PubMed ID: 33604759
[TBL] [Abstract][Full Text] [Related]
24. Endometrial cancer: molecular and therapeutic aspects.
Tsikouras P; Bouchlariotou S; Vrachnis N; Dafopoulos A; Galazios G; Csorba R; von Tempelhoff GF
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):1-9. PubMed ID: 23433742
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant treatment of endometrial cancer today.
Aoki Y; Kanao H; Wang X; Yunokawa M; Omatsu K; Fusegi A; Takeshima N
Jpn J Clin Oncol; 2020 Jul; 50(7):753-765. PubMed ID: 32463094
[TBL] [Abstract][Full Text] [Related]
26. Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.
Gordhandas S; Zammarrelli WA; Rios-Doria EV; Green AK; Makker V
J Natl Compr Canc Netw; 2023 Feb; 21(2):217-226. PubMed ID: 36791759
[TBL] [Abstract][Full Text] [Related]
27. Emerging drugs for endometrial cancer.
Amadio G; Masciullo V; Ferrandina MG; Scambia G
Expert Opin Emerg Drugs; 2014 Dec; 19(4):497-509. PubMed ID: 25330855
[TBL] [Abstract][Full Text] [Related]
28. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
30. Impact of the new molecular classification of endometrial cancer: A French cohort study.
Benichou J; Schwall C; Sastre-Garau X; Méreaux J; Miailhe G; Bendifallah S; Haddad B; Touboul C; Mitri-Frangieh R; Dabi Y
Gynecol Oncol; 2022 Sep; 166(3):515-521. PubMed ID: 35843738
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant therapy for early endometrial cancer - who benefits the most from a radiation therapy?
Michalak M; Warenczak Florczak Z; Staszewska-Nowak A; Roszak A
Ginekol Pol; 2020; 91(1):6-12. PubMed ID: 32039461
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; Casado Saenz E
Cancer Chemother Pharmacol; 2020 Mar; 85(3):477-486. PubMed ID: 31950214
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers as prognostic factors in endometrial cancer.
Dobrzycka B; Terlikowski SJ
Folia Histochem Cytobiol; 2010 Sep; 48(3):319-22. PubMed ID: 21071332
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
Hogberg T
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
[TBL] [Abstract][Full Text] [Related]
35. Ixabepilone for the treatment of endometrial cancer.
Marchetti C; Piacenti I; Imperiale L; De Felice F; Boccia S; Di Donato V; Perniola G; Monti M; Palaia I; Muzii L; Benedetti Panici P
Expert Opin Investig Drugs; 2016; 25(5):613-8. PubMed ID: 26949829
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Therapy for High-risk Endometrial Carcinoma.
Perera J; Hoskin P
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):560-566. PubMed ID: 34112584
[TBL] [Abstract][Full Text] [Related]
37. What's new in systemic therapy for endometrial cancer.
Kieser K; Oza AM
Curr Opin Oncol; 2005 Sep; 17(5):500-4. PubMed ID: 16093803
[TBL] [Abstract][Full Text] [Related]
38. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
39. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
Prendergast EN; Holman LL; Liu AY; Lai TS; Campos MP; Fahey JN; Wang X; Abdelaal N; Rao JY; Elvin JA; Moore KM; Konecny GE; Cohen JG
Gynecol Oncol; 2019 Sep; 154(3):461-466. PubMed ID: 31257009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
